Date: August 12, 2026

To	**To**
BSE Limited	**National Stock Exchange of India Limited**
25th Floor, PJ Towers	**Exchange Plaza, C-1, Block G**
Dalal Street,	**Bandra Kurla Complex, Bandra (E)**
Mumbai – 400001	**Mumbai – 400051**
Scrip Code: 524654	**Symbol: NATCAPSUQ**

Subject: Outcome of the Board Meeting held on Wednesday August 12, 2026.

This is to inform you that the Board of Directors at their meeting held on **Wednesday August 12, 2026**, have:

1. Approved the Unaudited Consolidated & Standalone Financial Results of the Company for the Quarter ended June 30, 2026.

2. **Preferential issue of warrants:**

   a. The Preferential Issue of up to 1,25,000 (One Lakh Twenty Five Thousand Only) **Equity Shares** of Face Value of ₹10/- each (Rupees Ten Only) to the person(s) belonging to the promoter /promoter group at an issue price of ₹160 (Rupees One Hundred Sixty Only) price determined as per the SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2018, subject to the approval of members in the General Meeting and other statutory and regulatory approvals whereas necessary and applicable.

   Further, the details as required under Regulation 30 of the Listing Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, is enclosed as **Annexure A.**

   b. The issuance of 5,00,000 (Five Lakh only) **Convertible Warrants** each convertible into, 1 (one) fully paid-up equity share of the Company of face value of ₹10/- each (Rupees Ten Only) to the person(s) belonging to the promoter/promoter group of the company, on a preferential basis (" Preferential Issue") at an issue price of ₹160/- (Rupees One Hundred Sixty Only) price determined as per the SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2018, Minimum amount of ₹40/- (Rupees Fourty Only) which is equivalent to 25% of warrant Issue Price shall be paid at the time of subscription and allotment of each warrant, Further subject to the approval of members in the General Meeting and other statutory and regulatory approvals whereas necessary and applicable.

   Further, the details as required under Regulation 30 of the Listing Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, is enclosed as **Annexure A.**

3. Considered and approved the draft **Notice of Extra Ordinary General Meeting** of the Members of the Company scheduled to be held on **Wednesday, 9th September, 2026**, at the registered office of the company the relevant details will be submitted to the Stock Exchange in due course of time.

4. The Board of Directors has appointed M/S Deepak Sadhu, Practicing Company Secretaries (COP: 14992), as the Scrutinizer to the E-voting Process.

The Board Meeting commenced at 3:30 PM and concluded at 6:00 PM.

Kindly take the aforesaid information on record in compliance of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Yours Faithfully,

For Natural Capsules Limited

AKSHAY DUTTA Digitally signed by AKSHAY DUTTA Date: 2026.08.12 18:04:43 +05'30'

Akshay Dutta
Company Secretary and Compliance Officer
M.No. A80481

NATURAL CAPSULES LIMITED

NATURAL CAPSULES LIMITED

CORP & REGD OFFICE : " TRIDENT TOWERS" No. 23, 4th Floor, 100 feet Road, Jayanagar 2nd Block, Bangalore-560011
Phone : 080-26561562 / 1571 /1573 /581 URL : www.naturalcapsules.com Email : info@naturalcapsules.com, CIN No. : L85110KA1993PLC014742

Annexure-A

The details as required to be disclosed under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

<table>
<tr><td>Sl. No.</td><td>Particulars</td><td>Remarks</td></tr>
<tr><td>1.</td><td>Type of Securities proposed to be issued (viz., equity shares, convertibles etc.)</td><td>1. Equity Shares of face value ₹10/- each
2. Warrants convertible into Equity Shares of face value ₹10/- each i.e. 1 Equity Share per 1 Warrant.</td></tr>
<tr><td>2.</td><td>Type of Issuance</td><td>Preferential issuance under Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018</td></tr>
<tr><td>3.</td><td>Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)</td><td>1. 1,25,000 Equity Shares at issue price of ₹160/- per Equity Share aggregating to ₹2 crore to the persons belonging to Promoter/Promoter Group category.
2. 5,00,000 Warrants, convertible into equivalent number of equity shares at an issue price of ₹160/- per Equity Share ("Warrant Exercise Price") aggregating to ₹8 crore to the persons belonging to Promoter/Promoter Group category.</td></tr>
<tr><td>4.</td><td colspan="2">Additional details in case of preferential issue</td></tr>
<tr><td>4A.</td><td>Name of the Investors - EQUITY</td><td>1. Mr. Sunil L Mundra (Promoter/Promoter Group) – 1,25,000 Equity Shares.</td></tr>
<tr><td>4B.</td><td>Name of the Investors – CONVERTIBLE WARRANTS</td><td>1. Mr. Sunil L Mundra (Promoter/Promoter Group) – 5,00,000 Warrants, convertible into equivalent number of equity shares.</td></tr>
<tr><td>4C.</td><td>Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors.</td><td>
<table>
<tr><td>Particulars</td><td colspan="2">Pre-Preferential Allotment</td><td colspan="2">*Post-Preferential Allotment</td></tr>
<tr><td></td><td>No. of shares held</td><td>%held</td><td>No. of shares held</td><td>%held</td></tr>
<tr><td colspan="5">Promoter/Promoter Group Category</td></tr>
<tr><td>Mr. Sunil L Mundra</td><td>6,02,290</td><td>5.79%</td><td>12,27,290</td><td>11.12%</td></tr>
</table>
*Assuming full conversion of Warrants into equity shares

The post issue shareholding pattern has been prepared with shareholding as on 10th August, 2026, on the basis that the proposed allottees would have subscribed to all the warrants and have been allotted all the equity shares upon conversion of warrants.

₹160/- per Equity Share price determined as per the SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2018</td></tr>
</table>

AKSHAY DUTTA Digitally signed by AKSHAY DUTTA Date: 2026.08.12 18:06:10 +05'30'

CORP & REGD OFFICE : " TRIDENT TOWERS" No. 23, 4th Floor, 100 feet Road, Jayanagar 2nd Block, Bangalore-560011
Phone : 080-26561562 / 1571 /1573 /581 URL : www.naturalcapsules.com Email : info@naturalcapsules.com, CIN No. : L85110KA1993PLC014742

4D.	**Issue Price – Equity & Convertibles Warrants**	₹160/- (Rupees One Hundred Sixty Only) Price determined as per the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
4E.	**In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument**	Each Warrant would be convertible into one equity share and the rights attached to the Warrants can be exercised at any time within a period of 18 (Eighteen) months from the date of allotment of Warrants. An amount equivalent to 25% of the Warrant Exercise Price shall be payable at the time of subscription and allotment of each Warrant and the balance 75% of the Warrant Exercise Price shall be payable by the Warrant holder against each Warrant at the time of allotment of Equity Shares pursuant to exercise of the options attached to Warrant(s) to subscribe to the Equity Share(s). The amount paid against Warrants shall be adjusted / set-off against the issue price for the resultant Equity Shares. In case the Warrant holder fails to exercise the Warrant within a period of 18 months from date of allotment of Warrant, the Warrant shall lapse and the 25% of the Warrant Exercise Price paid at the time of issuance of Warrant will be forfeited by the Company.
4F.	**Any cancellation or termination of proposal for issuance of securities including reasons thereof.**	Not applicable

AKSHAY DUTTA Digitally signed by AKSHAY DUTTA Date: 2026.08.12 18:05:46 +05'30'

P. CHANDRASEKAR LLP
Chartered Accountants

Independent Auditor's Limited Review Report on standalone unaudited financial results of for the quarter ended 30 June 2026

To the Board of Directors M/s. Natural Capsules Limited-Bengaluru

1. We have received the accompanying statement of unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** ("the company") for the quarter ended June 2026 ("the Statement"), which are included in the accompanying statement of unaudited financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.

2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting "prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard as specified under section 133 of the Companies Act 2013 read with relevant rules issued thereunder other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed , or that it contains any material misstatement.

For **P. Chandrasekar LLP**
Chartered Accountants
FRN No: 000580S/S200066

Rajesh D
Partner
Membership No:234709
UDIN : 26234709UEWCVO9656
Place: Bengaluru
Date: August 12, 2026

P. CHANDRASEKAR LLP Bangalore-42 Chartered Accountants

Bangalore / Chennai / Hyderabad

Head Office:
S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore - 560042
✆ : 080-25585443 / 25597494

P. CHANDRASEKAR LLP
Chartered Accountants

Independent Auditor's Limited Review Report on Consolidated unaudited financial results for the quarter ended 30th June 2026

To the Board of Directors M/s. Natural Capsules Limited-Bengaluru

1. We have received the accompanying statement of Consolidated unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** (the Parent) and its subsidiaries (the Parent and its subsidiaries together referred to as the Group), for the quarter ended June 2026 ("the Statement"), which are included in the accompanying statement of consolidated unaudited Financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.

2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting "prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our Responsibility is to issue a report on the statement of consolidated unaudited financial results based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	**Relationship**
Natural Phyto Pharma Private Limited	Subsidiary
Natural Biogenex Private Limited	Subsidiary

5. The accompanying Statement includes the unaudited financial statements and other financial information, In respect of two subsidiaries, whose financial statements, without giving the effect to elimination of intra group transactions, Include total revenue of 10.26 lacs and net loss after tax of Rs.45.05 lacs, as considered in the consolidated unaudited financial results June 2026.

P. CHANDRASEKAR LLP Bangalore-42 Chartered Accountants

Head Office:
S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore - 560042
✆ : 080-25585443 / 25597494

6. We did not review the interim financial results of one subsidiary Natural Phyto Pharma Private Limited included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs.2.96 lacs as at 30th June 2026 and total revenues of Rs. Nil for the quarter ended 30th June 2026, total net profit after tax of Rs. Nil for the quarter ended 30th June 2026 as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports furnished by the management. In our opinion and according to the Information and explanations given to us by management, these financial statements and other financial information are not material to the Group. Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the financial information certified by management.

7. Based on our review conducted as above and based on the consideration of the review financial results/financial information certified by the Management as given above in point no.6, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with applicable Indian accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Chandrasekar LLP
Chartered Accountants
FRN No: 000580S/S200066

Rajesh D
Partner
Membership No: 234709
UDIN: 26234709GXDCAR7370

P. CHANDRASEKAR LLP Bangalore-42 Chartered Accountants

Place: Bengaluru
Date: August 12, 2026

Head Office:
S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore - 560042
✆ : 080-25585443 / 25597494

NATURAL CAPSULES LIMITED
TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026.

Rs in Lakhs

Sl. No.	PARTICULARS	Quarter Ended			Year Ended
		30th June 2026	31st Mar 2026	30th June 2025	31st Mar 2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue from operations	4,302.07	5,080.14	4,424.29	17,377.09
2	Other Income	230.84	212.54	169.08	765.09
3	**Total Income (1+2)**	**4,532.91**	**5,292.68**	**4,593.37**	**18,142.18**
4	**Expenses**				
	a) Cost of Material consumed	2,173.42	2,155.91	2,210.06	8,741.64
	b) (Increase) / Decrease in stock in trade	-128.87	416.31	63.97	-20.92
	c) Purchase of stock-in-trade	-	-	-	-
	d) Employees benefits expense	333.58	405.96	361.30	1,528.30
	f) Finance cost	144.03	148.91	135.75	575.28
	g) Depreciation	209.91	206.04	199.02	816.41
	h) Other Expenses	1,234.60	1,216.32	1,275.48	4,994.85
	Total Expenses	**3,966.67**	**4,549.46**	**4,245.58**	**16,635.55**
5	**Profit from ordinary activities after finance costs but before exceptional items**	**566.24**	**743.23**	**347.79**	**1,506.63**
6	Exceptional Items Income / (Expenses)	-	-	-	-
7	**Profit from ordinary activities before tax**	**566.24**	**743.23**	**347.79**	**1,506.63**
8	**Tax Expense**	**162.61**	**191.42**	**95.49**	**385.24**
	- Current Tax	146.18	186.10	88.38	362.36
	-Income tax (Prior year)	-	-	-	-
	- Deferred Tax	16.43	5.33	7.11	22.88
9	**Net Profit (+) / Loss (-) from ordinary activities after tax**	**403.63**	**551.81**	**252.30**	**1,121.39**
10	**Other Comprehensive income (OCI)**				
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-5.13	-	-5.13
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-
	Total Other Comprehensive Income (OCI) for the period	-	**-5.13**	-	**-5.13**
11	**Total Comprehensive Income (OCI) for the period**	**403.63**	**546.68**	**252.30**	**1,116.26**
12	Paid-Up Equity Share Capital (face value per share Rs.10/-)	1,041.12	1,038.62	1,034.12	1,038.62
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-				
	(a) Basic	3.89	5.33	2.44	10.79
	(b) Diluted	3.88	5.32	2.44	10.79

Note:

1 The above standalone financial results of Natural Capsules Limited (the Company) for the quarter ended 30th June 2026 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 12th August 2026. The above results have been subjected to "Limited Review" by the Statutory Auditors of the Company and they have expressed an unmodified opinion.

2 The above standalone financial results for the quarter ended 30th June, 2026 have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above standalone Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.

3 During the quarter ended 30th June 2026 an ex-employee has exercised 25,000 equity shares as ESOP Options and the same being allotted to him.

4 Previous years figures have been regrouped wherever necessary.

5 Position of investor complaints for the quarter ended 30th June, 2026

Particulars	
Pending as on 01.04.2026	Nil
Received during the quarter	Nil
Resolved during the quarter	Nil
Pending as on 30.06.2026	Nil

For and on behalf of the Board

Sunil L Mundra
Managing Director
DIN:00214304
Place : Bangalore
Date : 12-08-2026

CAPSULES LIMITED

NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

Rs in Lakhs

Sl. No.	PARTICULARS	Quarter Ended			Year Ended
		30th Jun 2026	31st Mar 2026	30th Jun 2025	31st Mar 2026
		Unudited	Audited	Unudited	Audited
1	Revenue from operations	4,871.19	5,845.33	4,520.31	18,720.46
2	Other Income	235.18	76.40	35.85	173.16
3	**Total Income (1+2)**	**5,106.37**	**5,921.72**	**4,556.16**	**18,893.63**
4	**Expenses**				
	a) Cost of Material consumed	2,891.71	2,946.82	2,358.03	10,322.91
	b) (Increase) / Decrease in stock in trade	-296.21	601.47	-0.65	-88.14
	c) Purchase of stock-in-trade	-	-	-	-
	d) Employees benefits expense	523.64	547.96	497.77	2,100.46
	f) Finance cost	497.35	288.98	253.03	1,094.88
	g) Depreciation	433.09	428.13	421.18	1,714.34
	h) Other Expenses	1,640.08	1,616.00	1,633.23	6,541.21
	Total Expenses	**5,689.66**	**6,429.37**	**5,162.60**	**21,685.65**
5	**Profit from ordinary activities after finance costs but before exceptional items**	-583.29	-507.65	-606.44	-2,792.02
6	Exceptional Items Income / (Expenses)	-	-	-	-
7	**Profit from ordinary activities before tax**	**-583.29**	**-507.65**	**-606.44**	**-2,792.02**
8	**Tax Expense**	**-8.91**	**-9.97**	**-48.39**	**-325.68**
	- Current Tax	146.18	186.10	88.38	362.36
	-Income tax (Prior year)	-	-	-	-
	- Deferred Tax	-155.09	-196.07	-136.77	-688.04
9	**Net Profit (+) / Loss (-) from ordinary activities after tax**	**-574.38**	**-497.68**	**-558.05**	**-2,466.34**
10	**Other Comprehensive income (OCI)**				
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-0.55	-	-0.55
	b) Items that will be reclassified to profit or loss (net of tax)				
	Total Other Comprehensive Income (OCI) for the period	-	**-0.55**	-	**-0.55**
11	**Total Comprehensive Income (OCI) for the period**	**-574.38**	**-498.23**	**-558.05**	**-2,466.89**
	Profit for the year attributable to:				
	Shareholders of the Company	-397.62	-344.53		-1,707.36
	Non-Controlling Interest	-176.76	-153.15		-758.98
		-574.38	**-497.68**		**-2,466.34**
	Other Comprehensive Income for the year attributable to:				
	Shareholders of the Company	-	-0.38		-0.38
	Non-Controlling Interest	-	-0.17		-0.17
		-	**-0.55**		**-0.55**
	Total Comprehensive Income for the year attributable to:				
	Shareholders of thé Company	-397.62	-344.91		-1,707.74
	Non-Controlling Interest	-176.76	-153.32		-759.15
		-574.38	**-498.23**		**-2,466.89**
12	Paid-Up Equity Share Capital (face value per share Rs.10/-)	1,041.12	1,038.62	1,034.12	1,038.62
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-				
	(a) Basic	-5.55	-4.82	-5.40	-23.84
	(b) Diluted	-5.54	-4.80	-5.40	-23.78

Note:

1. The above consolidated financial results of Natural Capsules Limited (the Company) for the quarter ended 30th June 2026 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 12th August 2026. The above results have been subjected to "Limited Review" by the Statutory Auditors of the Company and they have expressed unmodified opinion.
2. The above consolidated financial results for the quarter ended 30th June , 2026 have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above audited consolidated Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
3. During the quarter ended 30th June 2026 an ex-employee has exercised 25,000 equity shares as ESOP Options and the same being allotted to him.
4. Previous years figures have been regrouped wherever necessary.
5. Position of investor complaints for the quarter ended 30th June, 2026

Particulars	
Pending as on 01.04.2026	Nil
Received during the quarter	Nil,
Resolved during the quarter	Nil
Pending as on 30-06-2026	Nil

For and on behalf of the Board

Sunil L Mundra
Managing Director
DIN: 00214304
Place: Bangalore
Date : 12-08-2026

CAPSULES LIMITED NATURAL

NATURAL CAPSULES LIMITED
TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

CONSOLIDATED SEGMENT WISE REVENUE, RESULTS & CAPITAL EMPLOYED

Rs in Lakhs

PARTICULARS	Quarter Ended			Year Ended
	30th Jun 2026	31st Mar 2026	30th Jun 2025	31st Mar 2026
	Unaudited	Audited	Unaudited	Audited
1. Segment Revenue				
(a) Capsules	4,302.07	5,080.14	4,424.29	17,377.09
(b) API	569.12	765.18	96.02	1,343.37
(c) Unallocated	-	-		
Total	**4,871.19**	**5,845.33**	**4,520.31**	**18,720.46**
Less: Inter Segment Revenue	-	-	-	-
Income from Operations	**4,871.19**	**5,845.33**	**4,520.31**	**18,720.46**
2. Segment Results, Profit(+)/Loss (-) before tax and interest from each segment				
(a) Capsules	710.27	892.14	483.54	2,081.91
(b) API	-804.11	-934.56	-698.55	-3,132.83
(c) Unallocated	-	-	-	-
Total	**-93.85**	**-42.42**	**-215.01**	**-1,050.92**
Less: (i) Interest	497.35	473.05	399.34	1,772.81
(ii) Other Un-allocable Expenditure	-	-	-	-
(iii) Un-allocable Income	7.91	7.82	7.91	31.71
Total Profit Before Tax	**-583.29**	**-507.65**	**-606.44**	**-2,792.02**
3. Segment Assets				
(a) Capsules	19,032.41	18,172.24	19,166.00	18,172.24
(b) API	24,650.43	24,241.60	22,690.17	24,241.60
(c) Unallocated	-	-	-	-
(d) Others	1.94	1.94	1.85	1.94
Total	**43,684.78**	**42,415.78**	**41,858.02**	**42,415.78**
4. Segment Liabilities				
(a) Capsules	6,168.20	5,319.05	5,216.04	5,319.05
(b) API	2,748.64	2,189.39	720.20	2,189.39
(c) Unallocated	-	-	-	-
(d) Others	0.94	0.94	0.94	0.94
Total	**8,917.78**	**7,509.38**	**5,937.18**	**7,509.38**
5. Capital Employed (Segment Assets-Segment Liabilities)				
(a) Capsules	12,864.21	12,853.19	13,949.96	12,853.19
(b) API	21,901.80	22,052.21	21,969.97	22,052.21
(c) Unallocated	-	-	-	-
(d) Others	-	-	-	-
Total	**34,766.00**	**34,905.40**	**35,919.93**	**34,905.40**

For and on behalf of the Board

CAPSULES LIMITED NATURAL

Sunil L Mundra
Managing Director
DIN: 00214304
Place: Bangalore
Date : 12-08-2026